The Management Board of Celesio AG has resolved today to declare towards Bayerische Börse AG the revocation of Celesio AG’s consent to the listing in the market segment “m:access” and to the inclusion of the shares of Celesio AG in the unofficial market of the Munich stock exchange.
The listing of Celesio shares in the market segment “m:access” is expected to end with the expiry of 29 July 2016 and the inclusion in the unofficial market on 31 March 2017.
The Management Board also resolved to take the necessary steps in August 2016 to end the listing of Celesio AG’s shares in the regulated unofficial market segment “Primärmarkt” of Börse Düsseldorf AG and the inclusion of Celesio shares in the unofficial market of the Düsseldorf stock exchange. The listing of Celesio shares in the Düsseldorf unofficial market segment “Primärmarkt” will then be terminated at the end of September 2016 and the inclusion in the unofficial market on 31 March 2017.
The existing inclusion of Celesio shares in the unofficial markets of the stock exchanges in Hamburg and Hannover was not initiated by Celesio AG and will hence not be affected.
About the Celesio Group
Celesio is a leading international wholesale and retail company and provider of logistics and services to the pharmaceutical and healthcare sectors. The proactive and preventive approach ensures that patients receive the products and support that they require for optimum care. With more than 38,000 employees, Celesio operates in 14 countries around the world. Every day, the group serves over 2 million customers – at about 2,200 pharmacies of its own and over 4,300 participants in brand partnership schemes. With 135 wholesale branches, Celesio supplies 65,000 pharmacies and hospitals every day with up to 130,000 pharmaceutical products. The services benefit a patient pool of about 15 million per day.
McKesson Corporation, San Francisco, USA, is the majority shareholder in Celesio AG. The company acquired more than 75 percent of Celesio AG shares in February 2014. McKesson provides solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services.
- Claire Salmons
- Head of External Communications